Lyra Therapeutics (NASDAQ:LYRA) just reported results for the first quarter of 2024. Lyra Therapeutics reported earnings per share of -35 cents. This was below the analyst estimate for EPS of -26 ...
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic ...